Mirae Asset Global Etfs Holdings Ltd. Uro Gen Pharma Ltd. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 14,643 shares of URGN stock, worth $191,823. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,643Holding current value
$191,823% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding URGN
# of Institutions
119Shares Held
39.3MCall Options Held
158KPut Options Held
161K-
Rtw Investments, LP New York, NY3.56MShares$46.6 Million1.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.3MShares$43.2 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.08MShares$40.4 Million0.78% of portfolio
-
Great Point Partners LLC Greenwich, CT2.91MShares$38.1 Million12.93% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.45MShares$32.1 Million0.11% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $298M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...